Quick Answer
Autolus Therapeutics plc reported Cash And Cash Equivalents At Carrying Value of $104.13 million for the year ending 2025.
- Autolus Therapeutics plc showed a decrease of -54.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Autolus Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2021 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $343.03 million | Q2 2023: $307.50 million | Q3 2023: $256.42 million | Q1 2024: $758.53 million | Q2 2024: $705.94 million | Q3 2024: $657.07 million | Q1 2025: $95.80 million | Q2 2025: $123.83 million | Q3 2025: $86.12 million.
- Over the full 11 years of available data (2021 to 2025), Autolus Therapeutics plc's Cash And Cash Equivalents At Carrying Value has declined by 66.4%.
- Historical annual values: Fiscal year 2025: $104.13 million | Fiscal year 2024: $227.38 million | Fiscal year 2023: $239.57 million | Fiscal year 2023: $256.42 million | Fiscal year 2023: $307.50 million | Fiscal year 2023: $343.03 million | Fiscal year 2022: $382.44 million | Fiscal year 2022: $163.05 million | Fiscal year 2022: $216.44 million | Fiscal year 2022: $268.56 million | Fiscal year 2021: $310.34 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: